Eric W. Thomas

Array ( [id] => 4497458 [patent_doc_number] => 07947807 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-05-24 [patent_title] => 'Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3)' [patent_app_type] => utility [patent_app_number] => 12/284245 [patent_app_country] => US [patent_app_date] => 2008-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11509 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/947/07947807.pdf [firstpage_image] =>[orig_patent_app_number] => 12284245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5270990 [patent_doc_number] => 20090074766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-03-19 [patent_title] => 'Methods of inhibiting HIV-2 infection' [patent_app_type] => utility [patent_app_number] => 12/283482 [patent_app_country] => US [patent_app_date] => 2008-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 36632 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 33 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0074/20090074766.pdf [firstpage_image] =>[orig_patent_app_number] => 12283482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6340138 [patent_doc_number] => 20100247558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-30 [patent_title] => 'PEPTIDES INDUCING A CD4i CONFORMATION IN HIV gp120 WHILE RETAINING VACANT CD4 BINDING SITE' [patent_app_type] => utility [patent_app_number] => 12/675334 [patent_app_country] => US [patent_app_date] => 2008-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17232 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0247/20100247558.pdf [firstpage_image] =>[orig_patent_app_number] => 12675334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 111102 [patent_doc_number] => 07718180 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-05-18 [patent_title] => 'Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site' [patent_app_type] => utility [patent_app_number] => 12/229863 [patent_app_country] => US [patent_app_date] => 2008-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 20924 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/718/07718180.pdf [firstpage_image] =>[orig_patent_app_number] => 12229863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5520909 [patent_doc_number] => 20090028890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-29 [patent_title] => 'Immunogenic composition and method of developing a vaccine based on portions of the HIV matrix protein' [patent_app_type] => utility [patent_app_number] => 12/229865 [patent_app_country] => US [patent_app_date] => 2008-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 20921 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0028/20090028890.pdf [firstpage_image] =>[orig_patent_app_number] => 12229865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7997043 [patent_doc_number] => 08080369 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-12-20 [patent_title] => 'Methods for activating peripheral blood mononuclear cells (PBMCs) by administering human immunodeficiency virus (HIV) Tat under physiological oxygen levels' [patent_app_type] => utility [patent_app_number] => 12/196663 [patent_app_country] => US [patent_app_date] => 2008-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15448 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/080/08080369.pdf [firstpage_image] =>[orig_patent_app_number] => 12196663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5575010 [patent_doc_number] => 20090142371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-06-04 [patent_title] => 'HIV RECOMBINANT VACCINE' [patent_app_type] => utility [patent_app_number] => 12/195778 [patent_app_country] => US [patent_app_date] => 2008-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 11785 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0142/20090142371.pdf [firstpage_image] =>[orig_patent_app_number] => 12195778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5473655 [patent_doc_number] => 20090246821 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-10-01 [patent_title] => 'PEROXIREDOXIN DRUGS FOR TREATMENT OF HIV-1 INFECTION AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/195103 [patent_app_country] => US [patent_app_date] => 2008-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 15381 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0246/20090246821.pdf [firstpage_image] =>[orig_patent_app_number] => 12195103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4521075 [patent_doc_number] => 07951377 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-05-31 [patent_title] => 'Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens' [patent_app_type] => utility [patent_app_number] => 12/192015 [patent_app_country] => US [patent_app_date] => 2008-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 109 [patent_figures_cnt] => 46 [patent_no_of_words] => 13434 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/951/07951377.pdf [firstpage_image] =>[orig_patent_app_number] => 12192015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5526797 [patent_doc_number] => 20090196874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-08-06 [patent_title] => 'ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS' [patent_app_type] => utility [patent_app_number] => 12/190802 [patent_app_country] => US [patent_app_date] => 2008-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 24122 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0196/20090196874.pdf [firstpage_image] =>[orig_patent_app_number] => 12190802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5533479 [patent_doc_number] => 20090233267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-09-17 [patent_title] => 'Methylated Tat Polypeptides and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 12/190414 [patent_app_country] => US [patent_app_date] => 2008-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 25078 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0233/20090233267.pdf [firstpage_image] =>[orig_patent_app_number] => 12190414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6038442 [patent_doc_number] => 20110091491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-21 [patent_title] => 'HIV-1 GP41 NEUTRALIZATION DOMAIN AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/672585 [patent_app_country] => US [patent_app_date] => 2008-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8437 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0091/20110091491.pdf [firstpage_image] =>[orig_patent_app_number] => 12672585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5429071 [patent_doc_number] => 20090088381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-04-02 [patent_title] => 'COMPOSITIONS CONTAINING ANTI-HIV PEPTIDES AND METHODS FOR USE' [patent_app_type] => utility [patent_app_number] => 12/184409 [patent_app_country] => US [patent_app_date] => 2008-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 15168 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0088/20090088381.pdf [firstpage_image] =>[orig_patent_app_number] => 12184409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5336756 [patent_doc_number] => 20090053220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-02-26 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE INHIBITION OF HIV INFECTION OF T CELLS' [patent_app_type] => utility [patent_app_number] => 12/182808 [patent_app_country] => US [patent_app_date] => 2008-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13363 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0053/20090053220.pdf [firstpage_image] =>[orig_patent_app_number] => 12182808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5296006 [patent_doc_number] => 20090010932 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-08 [patent_title] => 'GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV' [patent_app_type] => utility [patent_app_number] => 12/179399 [patent_app_country] => US [patent_app_date] => 2008-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 27388 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0010/20090010932.pdf [firstpage_image] =>[orig_patent_app_number] => 12179399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5290431 [patent_doc_number] => 20090023161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-22 [patent_title] => 'STRUCTURAL BASIS FOR TARGETING HIV-1 GAG PROTEINS TO THE PLASMA MEMBRANE FOR VIRUS ASSEMBLY' [patent_app_type] => utility [patent_app_number] => 12/175809 [patent_app_country] => US [patent_app_date] => 2008-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 11716 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0023/20090023161.pdf [firstpage_image] =>[orig_patent_app_number] => 12175809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5360533 [patent_doc_number] => 20090035327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-02-05 [patent_title] => 'Antibody Gene Transfer and Recombinant AAV Therefor' [patent_app_type] => utility [patent_app_number] => 12/145873 [patent_app_country] => US [patent_app_date] => 2008-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10097 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0035/20090035327.pdf [firstpage_image] =>[orig_patent_app_number] => 12145873 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5271005 [patent_doc_number] => 20090074781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-03-19 [patent_title] => 'Dengue virus peptide vaccine and methods of preparing and using the same' [patent_app_type] => utility [patent_app_number] => 12/156908 [patent_app_country] => US [patent_app_date] => 2008-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9633 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0074/20090074781.pdf [firstpage_image] =>[orig_patent_app_number] => 12156908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5490047 [patent_doc_number] => 20090291118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-11-26 [patent_title] => 'UNIVERSAL BARRIER TO PREVENT INFECTIONS FROM HUMAN IMMUNODEFICIENCY VIRUS' [patent_app_type] => utility [patent_app_number] => 12/126901 [patent_app_country] => US [patent_app_date] => 2008-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6100 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0291/20090291118.pdf [firstpage_image] =>[orig_patent_app_number] => 12126901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9046999 [patent_doc_number] => 08541553 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-24 [patent_title] => 'Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein' [patent_app_type] => utility [patent_app_number] => 12/601780 [patent_app_country] => US [patent_app_date] => 2008-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7418 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12601780 [rel_patent_id] =>[rel_patent_doc_number] =>)